Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases : Results From the RHEUVAX Cohort
Copyright © 2022 Mauro, Ciancio, Di Vico, Passariello, Rozza, Pasquale, Pantano, Cannistrà, Bucci, Scriffignano, Riccio, Patrone, Scalise, Ruscitti, Montemurro, Giordano, Vietri and Ciccia..
Objective: In the light of the current COVID-19 epidemic and the availability of effective vaccines, this study aims to identify factors associated with non-response to anti-SARS-CoV-2 vaccines as immunological alteration associated with immune rheumatic diseases (IRD) and immunosuppressive medications may impair the response to vaccination.
Methods: Volunteers in the health profession community with IRD, age, and sex-matched controls (CTRL) who underwent vaccination with two doses of BNT162b2 were recruited for this study. Anti-Trimeric Spike protein antibodies were assayed eight ± one weeks after the second vaccine dose. Univariate and logistic regression analyses were performed to identify factors independently associated with non-response and low antibody titers.
Results: Samples were obtained from 237 IRD patients (m/f 73/164, mean age 57, CI 95% [56-59]): 4 autoinflammatory diseases (AI), 62 connective tissue diseases (CTD), 86 rheumatoid arthritis (RA), 71 spondylarthritis (SpA) and 14 vasculitis (Vsc). 232 CTRL were recruited (m/f 71/161, mean age 57, CI 95% [56-58]). Globally, IRD had a lower seroconversion rate (88.6% vs 99.6%, CI 95% OR [1.61-5.73], p<0.001) and lower antibody titer compared to controls (median (IQR) 403 (131.5-1012) versus 1160 (702.5-1675), p<0.001). After logistic regression, age, corticosteroid (CCS), Abatacept and Mycophenolate Mofetil (MMF) use were associated with non-response. Lower antibody titer was associated with the use of MMF, ABA, CCS, Rituximab, tumor necrosis factor inhibitor, JAK inhibitors, and higher age.
Conclusion: The response to anti-SARS-CoV-2 vaccines is often impaired in IRD patients under treatment and may pose them at higher risk of severe COVID-19. Specific vaccination protocols are desirable for these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 18., Seite 901055 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mauro, Daniele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 06.07.2022 Date Revised 07.12.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.901055 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343051052 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343051052 | ||
| 003 | DE-627 | ||
| 005 | 20231226204930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.901055 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343051052 | ||
| 035 | |a (NLM)35784360 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mauro, Daniele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases |b Results From the RHEUVAX Cohort |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Mauro, Ciancio, Di Vico, Passariello, Rozza, Pasquale, Pantano, Cannistrà, Bucci, Scriffignano, Riccio, Patrone, Scalise, Ruscitti, Montemurro, Giordano, Vietri and Ciccia. | ||
| 520 | |a Objective: In the light of the current COVID-19 epidemic and the availability of effective vaccines, this study aims to identify factors associated with non-response to anti-SARS-CoV-2 vaccines as immunological alteration associated with immune rheumatic diseases (IRD) and immunosuppressive medications may impair the response to vaccination | ||
| 520 | |a Methods: Volunteers in the health profession community with IRD, age, and sex-matched controls (CTRL) who underwent vaccination with two doses of BNT162b2 were recruited for this study. Anti-Trimeric Spike protein antibodies were assayed eight ± one weeks after the second vaccine dose. Univariate and logistic regression analyses were performed to identify factors independently associated with non-response and low antibody titers | ||
| 520 | |a Results: Samples were obtained from 237 IRD patients (m/f 73/164, mean age 57, CI 95% [56-59]): 4 autoinflammatory diseases (AI), 62 connective tissue diseases (CTD), 86 rheumatoid arthritis (RA), 71 spondylarthritis (SpA) and 14 vasculitis (Vsc). 232 CTRL were recruited (m/f 71/161, mean age 57, CI 95% [56-58]). Globally, IRD had a lower seroconversion rate (88.6% vs 99.6%, CI 95% OR [1.61-5.73], p<0.001) and lower antibody titer compared to controls (median (IQR) 403 (131.5-1012) versus 1160 (702.5-1675), p<0.001). After logistic regression, age, corticosteroid (CCS), Abatacept and Mycophenolate Mofetil (MMF) use were associated with non-response. Lower antibody titer was associated with the use of MMF, ABA, CCS, Rituximab, tumor necrosis factor inhibitor, JAK inhibitors, and higher age | ||
| 520 | |a Conclusion: The response to anti-SARS-CoV-2 vaccines is often impaired in IRD patients under treatment and may pose them at higher risk of severe COVID-19. Specific vaccination protocols are desirable for these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a arthritis | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a connective tissue disease (CTD) | |
| 650 | 4 | |a rheumatic and muscoluskeletal disease | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Ciancio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Vico, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Passariello, Luana |e verfasserin |4 aut | |
| 700 | 1 | |a Rozza, Gelsomina |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquale, Maria Dora |e verfasserin |4 aut | |
| 700 | 1 | |a Pantano, Ilenia |e verfasserin |4 aut | |
| 700 | 1 | |a Cannistrà, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Bucci, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Scriffignano, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Riccio, Flavia |e verfasserin |4 aut | |
| 700 | 1 | |a Patrone, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Scalise, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Ruscitti, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Montemurro, Maria Vittoria |e verfasserin |4 aut | |
| 700 | 1 | |a Giordano, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Vietri, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccia, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 18., Seite 901055 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:18 |g pages:901055 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.901055 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 18 |h 901055 | ||